Cyril Berthet, Pharmaco-imaging Unit Director & Director of Pharmimage
26 septembre 2019 – 17h
Exciting recent developments have proven the unique promise offered by Targeted Radionuclide Therapy (TRT) for better precision medicine.
Whether given alone or in combination, TRT and immunotherapy will have an important role to play in the treatment of cancer patients in the future.
Dr. Cyril Berthet will present the tools & expertise available today for the preclinical assessment of TRT.
Discover how to facilitate the translation of new targeted radionuclide therapies into clinical practice.
Find out about preclinical targeted radiopharmaceuticals projects, including combination studies with chemotherapies or immune checkpoint inhibitors!
Key learning objectives
- Introduction to TRT
- Design & implementation of the radionuclide labeling of biological molecules of interest
- Binding study to select the preclinical models and population of patients expressing the target of interest
- Whole body biodistribution to evaluate the kinetic of in vivo specific binding
- Evaluation of targeted radiotherapy efficacy
- Benefit of radiotherapy and immunotherapy or chemotherapy combinationVitro/Vivo assays developed by Oncodesign for routine assessment of molecules.
About our speaker Cyril Berthet
Cyril Berthet is Pharmaco-imaging Unit Director & Director of Pharmimage Operations at Oncodesign.
He holds a PhD in Molecular and Cellular Biology from the University of Lyon, France. In 2002, he joined the Mouse Cancer Genetics Program at the National Cancer Institute in Frederick, US as a Research Associate. He joined Oncodesign in 2007 as a project leader and now manages strategic partnerships in therapeutic and biomarker discovery.